The Latest

TWiPO #63 – Interview with Dr. Javier Blanco

Twipo hosts and co-hosts interview Dr. Javier Blanco, SUNY Buffalo, about the toxic, long term effects that various chemotherapy drugs can have on heart tissue. 

TWiPO #64 – Interview with Dr. Lars Wagner

Dr. Timothy Cripe, along with cohosts Dr. Keri Streby, Dr. Nilay Shah and Dr. Ryan Roberts, interview special guest Dr. Lars Wagner, Chief of Pediatric Hematology/Oncology, University of Kentucky.

TWIPO #61 – Interview with Dr. Matthew Breen

TWIPO hosts and cohosts interview Dr. Matthew Breen, NC State Veterinary Medicine, on his research with various dog genomes, and whether or not dogs can “teach us new tricks” when it comes to cancer treatment.

TWiPO #62 – Interview with Dr. Uri Tabori

TWiPO hosts and cohosts interview Dr. Uri Tabori, Hospital for Sick Kids, Toronto, about the challenges that are unique to pediatric brain tumors and how preventative treatment and early diagnosis can be largely beneficial.  

Advocacy in Action

Solving Kids` Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC`s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma. 

Precision Medicine Advances for Children With Neuroblastoma

November 17, 2016

Next Generation Personalized Neuroblastoma Therapy gives hope to children with relapse or refractory disease.

TWIPO #60 – Interview with Dr. Josua Mendell

November 4, 2016
TWIPO hosts and cohosts interview Dr. Josh Mendell, who shares his knowledge with regard to the relationship between innate RNA biology and how it influences human disease.  

Interview With Dr. Sajid Qureshi

September 30, 2016
TWiPO Hosts and co-host interview Dr. Sajid Qureshi In this episode Dr. Qureshi provides a fascinating, first-hand glimpse into the successes and challenges of delivering quality care to larger, as well as remote, pediatric cancer populations.

Cutting-Edge Oncolytic Virus Therapy

Children with high grade brain tumors will soon be able to receive cutting-edge onocolytic virus therapy.